Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal 2026 revenue of $450.817 million as it expanded REDEMPLO commercialization and advanced its clinical pipeline. For the year ended September 30, ...
A $66.5 million noncash unrealized derivative loss primarily explains the net loss; adjusted EBITDA was $29.1 million. The $0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results